Quinidine

Background

• Inexpensive with restricted indications, causing it to be inaccessible in many areas globally
• Main manufacturer halted production in 2010
• Historically both supraventricular tachydysrhytmia, ventricular dysrhythmia, malaria treatment, many other first-line therapies have replaced its use
• An effective treatment and prevention strategy for:
  • Brugada syndrome arrhythmic electrical storm
  • Idiopathic ventricular fibrillation
  • Early repolarization syndrome (though NOT benign, see benign early repolarization)
  • Congenital short QT syndrome

Sources

</references>